TABLE 5.

Characteristics of pivotal trials.

Group	MRCT	Single
By countries
China	37 (20%)	15 (47%)
EU	56 (31%)	0
Japan	38 (21%)	16 (50%)
US	52 (28%))	1 (3%)
By product types
Biologics	60 (33%)	12 (38%)
Chemical drug	123 (67%)	20 (62%)
By tumor types
Hematologic malignancies	51 (28%)	10 (31%)
Solid tumors	132 (72%)	22 (69%)
By study phase
Phase 1–2	58 (32%)	28 (88%)
Phase 3	125 (68%)	4 (12%)
By number of regions
1	15 (8%)	–
2	26 (14%)	–
3	71 (39%)	–
4	47 (26%)	–
5	24 (13%)	–
Total	183 (85%)	32 (15%)